A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

Bristol-Myers Squibb

Summary

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria * Participants must have an ECOG performance status of 0 to 1. * Participants must have measurable disease by RECIST v1.1 (radiologically measured by the Investigator). * Participants must have documented histologically or cytologically confirmed advanced, unresectable/metastatic solid tumors, including NSCLC, HNSCC, TNBC, and HR+/HER2- breast cancer. Exclusion Criteria * Participants are eligible if CNS metastases have been treated and do not require immediate treatment or have been treated and have neurologically returned to baseline (except for residual signs or sympto…

Locations (20)

Local Institution - 0033
Irvine, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
323-865-3967
University of California, Irvine (UCI) Health - UC Irvine Medical Center
Orange, California
310-222-2222
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
412-864-7955
Sanford Cancer Center
Sioux Falls, South Dakota
605-328-8000
START - Dallas Fort Worth
Fort Worth, Texas
682-350-3010

Summary

Eligibility

Interventions

Locations (20)